Anna Campain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11929968/publications.pdf

Version: 2024-02-01

840776 1281871 1,013 11 11 11 citations h-index g-index papers 11 11 11 1289 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema. Ophthalmology, 2014, 121, 2473-2481.	5.2	270
2	Long-Term Outcomes of Treatment ofÂNeovascular Age-Related MacularÂDegeneration. Ophthalmology, 2015, 122, 1837-1845.	5.2	206
3	Two-Year Outcomes of "Treat and Extend―Intravitreal Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 1212-1219.	5.2	148
4	Comparison study of microarray meta-analysis methods. BMC Bioinformatics, 2010, 11, 408.	2.6	95
5	TWO YEAR OUTCOMES OF "TREAT AND EXTEND―INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2018, 38, 20-28.	1.7	83
6	Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). Ophthalmology, 2016, 123, 1399-1401.	5.2	68
7	Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. The Cochrane Library, 2018, 2018, CD011599.	2.8	37
8	Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. British Journal of Ophthalmology, 2016, 100, 1640-1645.	3.9	36
9	Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. British Journal of Ophthalmology, 2016, 100, 1000-1004.	3.9	32
10	Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily withÂRanibizumab. Ophthalmology, 2015, 122, 589-594.e1.	5.2	25
11	Intravitreal Therapy in Bilateral Neovascular Age-Related MacularÂDegeneration. Ophthalmology, 2014, 121, 2073-2074.	5.2	13